Search research articles
Contact Us
Filters
Showing results (51-60 of 261) with videos related to
Page
of 27
Sort By:
Clinicoeconomics and Outcomes Research : CEOR
|
September 24, 2014
Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
Machaon Bonafede, George J Joseph, Neel Shah, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 3, 2014
Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database
Andrew Howe, Laura Ten Eyck, Robert Dufour, et al.
BMC Cancer
|
July 10, 2008
TGFbeta induces apoptosis and EMT in primary mouse hepatocytes independently of p53, p21Cip1 or Rb status
Sharon Sheahan, Christopher O Bellamy, Stephen N Harland, et al.
BMC Cancer
|
November 21, 2007
Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest
Sharon Sheahan, Christopher O Bellamy, Donald R Dunbar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 2, 2011
Routinely obtained diagnostic material as a source of RNA for personalized medicine in lung cancer patients
Timothy D Andrews, Jan W Baird, William A H Wallace, et al.
Gigascience
|
October 23, 2025
SurGen: 1020 H&E-stained whole-slide images with survival and genetic markers
Craig Myles, In Hwa Um, Craig Marshall, et al.
Journal of Clinical Pathology
|
July 9, 2016
Could molecular pathology testing in lung cancer be more cost-effective?
Kathy Walsh, Yuan Chun Kheng, Anca Oniscu, et al.
Free Radical Biology & Medicine
|
February 14, 2002
Glutathione and p53 independently mediate responses against oxidative stress in ES cells
Jonathan P Coe, Irfan Rahman, Nathalie Sphyris, et al.
Scientific Reports
|
October 28, 2015
Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis
Wim Verleyen, Simon P Langdon, Dana Faratian, et al.
Vascular Health and Risk Management
|
December 22, 2018
Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
Dionne M Hines, Pallavi Rane, Jeetvan Patel, et al.
Page
of 27
Search research articles
Search
Showing results (51-60 of 261) with videos related to
Sort By:
Page
of 27
Clinicoeconomics and Outcomes Research : CEOR
|
September 24, 2014
Cost of tumor necrosis factor blockers per patient with rheumatoid arthritis in a multistate Medicaid population
Machaon Bonafede, George J Joseph, Neel Shah, et al.
Journal of Managed Care & Specialty Pharmacy
|
December 3, 2014
Treatment patterns and annual drug costs of biologic therapies across indications from the Humana commercial database
Andrew Howe, Laura Ten Eyck, Robert Dufour, et al.
BMC Cancer
|
July 10, 2008
TGFbeta induces apoptosis and EMT in primary mouse hepatocytes independently of p53, p21Cip1 or Rb status
Sharon Sheahan, Christopher O Bellamy, Stephen N Harland, et al.
BMC Cancer
|
November 21, 2007
Deficiency of G1 regulators P53, P21Cip1 and/or pRb decreases hepatocyte sensitivity to TGFbeta cell cycle arrest
Sharon Sheahan, Christopher O Bellamy, Donald R Dunbar, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
March 2, 2011
Routinely obtained diagnostic material as a source of RNA for personalized medicine in lung cancer patients
Timothy D Andrews, Jan W Baird, William A H Wallace, et al.
Gigascience
|
October 23, 2025
SurGen: 1020 H&E-stained whole-slide images with survival and genetic markers
Craig Myles, In Hwa Um, Craig Marshall, et al.
Journal of Clinical Pathology
|
July 9, 2016
Could molecular pathology testing in lung cancer be more cost-effective?
Kathy Walsh, Yuan Chun Kheng, Anca Oniscu, et al.
Free Radical Biology & Medicine
|
February 14, 2002
Glutathione and p53 independently mediate responses against oxidative stress in ES cells
Jonathan P Coe, Irfan Rahman, Nathalie Sphyris, et al.
Scientific Reports
|
October 28, 2015
Novel Monte Carlo approach quantifies data assemblage utility and reveals power of integrating molecular and clinical information for cancer prognosis
Wim Verleyen, Simon P Langdon, Dana Faratian, et al.
Vascular Health and Risk Management
|
December 22, 2018
Treatment patterns and patient characteristics among early initiators of PCSK9 inhibitors
Dionne M Hines, Pallavi Rane, Jeetvan Patel, et al.
Page
of 27